Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$4.12B |
| 2 |
Gilead Sciences
GILD
|
+$379M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$286M |
| 4 |
Amazon
AMZN
|
+$271M |
| 5 |
Meta Platforms (Facebook)
META
|
+$266M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$762M |
| 2 |
SPDR Gold Trust
GLD
|
+$410M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$400M |
| 4 |
QIHU
QIHOO 360 TECHNOLOGY CO LTD ADS RPSTG 3 CL A SHS
QIHU
|
+$227M |
| 5 |
Synchrony
SYF
|
+$195M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Staples | 2.31% |
| 2 | Technology | 1.26% |
| 3 | Financials | 1.12% |
| 4 | Healthcare | 1.04% |
| 5 | Consumer Discretionary | 0.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CLVS
1026
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
| $19.5M | 0.01% |
541,000
+263,500
| +95% | +$5.65M |
|
1027
CALL
Ionis Pharmaceuticals
IONS
$10.6B
| $19.5M | 0.01% |
531,000
-32,300
| -6% | -$1.01M |
|
|
CLVS
1028
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
| $19.4M | 0.01% |
538,800
+222,200
| +70% | +$4.77M |
|
|
DISH
1029
DELISTED
DISH Network Corp.
DISH
| $19.4M | 0.01% |
354,082
-84,868
| -19% | -$4.4M |
|
1030
CALL
Edgewell Personal Care
EPC
$1.31B
| $19.3M | 0.01% |
243,200
+189,800
| +355% | +$15.3M |
|
1031
PUT
Martin Marietta Materials
MLM
$37.9B
| $19.3M | 0.01% |
107,900
-40,600
| -27% | -$7.75M |
|
|
CAB
1032
CALL
DELISTED
Cabela's Inc
CAB
| $19.3M | 0.01% |
351,100
+267,000
| +317% | +$13.7M |
|
1033
State Street Financial Select Sector SPDR ETF
XLF
$56.6B
| $19.3M | 0.01% |
998,806
+634,492
| +174% | +$13.1M |
|
|
TRQ
1034
CALL
DELISTED
Turquoise Hill Resources Ltd
TRQ
| $19.3M | 0.01% |
648,530
+48,310
| +8% | +$1.56M |
|
1035
PUT
Norfolk Southern
NSC
$79.3B
| $19.3M | 0.01% |
198,400
-261,900
| -57% | -$23.8M |
|
|
HZNP
1036
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $19.2M | 0.01% |
1,061,023
+563,195
| +113% | +$11M |
|
1037
CALL
State Street SPDR S&P Dividend ETF
SDY
$22.1B
| $19.2M | 0.01% |
227,400
+4,300
| +2% | +$367K |
|
1038
PUT
Acuity Brands
AYI
$10.1B
| $19.2M | 0.01% |
72,400
-40,500
| -36% | -$10.8M |
|
1039
CNX Resources
CNX
$5.31B
| $19.1M | 0.01% |
1,195,100
+1,107,207
| +1,260% | +$16.4M |
|
1040
PUT
Franklin Templeton
BEN
$17.6B
| $19.1M | 0.01% |
536,600
-6,200
| -1% | -$219K |
|
|
CXO
1041
PUT
DELISTED
CONCHO RESOURCES INC.
CXO
| $19.1M | 0.01% |
138,900
-61,100
| -31% | -$7.74M |
|
1042
CALL
Novartis
NVS
$303B
| $19M | 0.01% |
269,179
-62,831
| -19% | -$4.58M |
|
|
MDCO
1043
PUT
DELISTED
Medicines Co
MDCO
| $19M | 0.01% |
503,700
+302,800
| +151% | +$11.4M |
|
|
LVLT
1044
CALL
DELISTED
Level 3 Communications Inc
LVLT
| $18.9M | 0.01% |
408,100
+152,900
| +60% | +$7.73M |
|
|
STMP
1045
PUT
DELISTED
Stamps.com, Inc.
STMP
| $18.9M | 0.01% |
199,700
+87,700
| +78% | +$7.6M |
|
|
AUY
1046
PUT
DELISTED
Yamana Gold, Inc.
AUY
| $18.8M | 0.01% |
4,354,000
-43,700
| -1% | -$225K |
|
1047
PUT
Factset
FDS
$10.7B
| $18.8M | 0.01% |
115,700
+20,600
| +22% | +$3.55M |
|
|
ADPT
1048
PUT
DELISTED
Adeptus Health Inc
ADPT
| $18.7M | 0.01% |
435,500
+328,000
| +305% | +$14.8M |
|
|
SYT
1049
PUT
DELISTED
Syngenta Ag
SYT
| $18.7M | 0.01% |
213,900
+111,400
| +109% | +$9.18M |
|
1050
PUT
Canadian Pacific Kansas City
CP
$84B
| $18.7M | 0.01% |
613,500
-910,000
| -60% | -$26.7M |
|
Similar funds
Jeff Yass's Q3 2016 Portfolio in Review
As of Q3 2016, Jeff Yass held 9,816 positions worth $207B, up 11% from $187B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Jeff Yass deployed $7.57B of net new capital in Q3 2016, opening 1,347 new positions and adding to 3,275 existing holdings. Its largest new stake was Bristol-Myers Squibb: 4,459,411 shares worth $240M.
By sector, the portfolio is most concentrated in Consumer Staples at 2.3% of assets, up from 0.28% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Apple, an estimated $762M trimmed.
- Jeff Yass's largest Q3 2016 buy was Bristol-Myers Squibb: 4,459,411 shares worth $240M.
- Jeff Yass added most to Procter & Gamble in Q3 2016, an estimated $4.12B increase.
- Jeff Yass's biggest Q3 2016 reduction was Apple, cutting an estimated $762M.
- Jeff Yass fully exited QIHOO 360 TECHNOLOGY CO LTD ADS RPSTG 3 CL A SHS in Q3 2016, selling an estimated $227M.
- Jeff Yass's ten largest holdings make up 27% of its $207B portfolio in Q3 2016.
- Jeff Yass opened 1,347 new positions and closed 1,488 in Q3 2016.
- Jeff Yass's portfolio value rose 11% quarter-over-quarter to $207B.
Based on Susquehanna International Group's 13F filing for Q3 2016, filed 14 Nov 2016.